Skip to content

Circadian Rhythm Disruption Effects on Smoke Inhalation

The Effects of Circadian Rhythm Disruption on the Inflammatory Response to Particulate Matter Exposure From Woodsmoke

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04955431
Enrollment
10
Registered
2021-07-08
Start date
2022-01-24
Completion date
2022-04-17
Last updated
2025-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammation, Sleep Deprivation, Circadian Rhythm Sleep Disorder, Shift Work Type, Smoke Inhalation

Brief summary

Particulate matter exposure during smoke inhalation provokes inflammatory immune responses in people exposed to burning biomass including fire fighters and civilians. Persistent occupational exposure to particulate matter represents a unique hazard for firefighters, underpinning a burgeoning research area. This trial will evaluate the effects of sleep deprivation and circadian rhythm disruption on the inflammatory response to woodsmoke associated particulate matter exposure. Participants will undergo 2 experimental trials in a randomized cross-over design. Participants will have either an 8-hour sleep opportunity or a 4-hour sleep opportunity prior to reporting to lab for a 45 minute simulated firefighting trial (wood smoke associated particulate matter filtered to 2.5 um at a concentration of 250 ug/m\^3, while exercising at a moderate intensity). The effects of sleep restriction and simulated firefighting will be measured.

Detailed description

Participants: Healthy college age males (n = 15), free from disordered sleep and without recent trans-meridian travel (within the last 2 weeks) will be recruited for this study. Participants will complete chronotype questionnaires (Morningness-Eveningness Questionnaire; MEQ, Munich Chronotype Questionnaire; MCTQ) to establish intermediate chronotypes. This will minimize the effect of circadian preference on the morning exposure to smoke. Participants will subsequently be outfitted with activity monitors (ActiCal) to monitor sleep and physical activity throughout the experimental duration. Participants will be asked to maintain a normal sleep schedule for at least 3 days leading up to the experimental trials and keep a sleep log to verify. Experimental Trials: Participants will undergo 2 experimental trials in a randomized cross-over design, with at least 1 week washout period between trials; 1) NS-250: Normal Sleep with exposure to woodsmoke at 250 µg/m\^3, and RS-250: Restricted Sleep with exposure to woodsmoke at 250 µg/m\^3. Participants will have an 8-hour sleep opportunity in their own home during the NS trials (22:00-06:00), and a 4-hour sleep opportunity during the RS trials (00:00-04:00). In all trials, participants will report to the laboratory at 07:30 the morning after the experimental sleep night. PM exposure will occur from 08:00-08:45 while cycling at 70% heart rate reserve (HRR) to simulate the physical demands of firefighting. Exhaled Breath Condensate (EBC): EBC will be collected using standardized 10 minute collection techniques. In order to preserve sample integrity for potentially labile biomarkers (e.g., oxidative stress), sample pH will be measured immediately prior to aliquoting in multiple cryotubes (500-700µl), flash freezing, and storage at -80 degrees C until further assay. Standardized biomarker panels for oxidative stress and inflammation will be performed using a single thaw approach. Inflammatory biomarker analysis: Blood will be collected into heparinized vacutainers before (PRE) and immediately following (POST) PM2.5 exposure and spun down for plasma collection. Plasma will be assayed for inflammatory biomarkers (interleukin (IL)-6, tumor necrosis factor (TNF)-α, pentraxin-3, and C-reactive protein (CRP)) using standard enzyme linked immunosorbent assays (ELISA). Circadian Rhythm Assessment: Throughout the experimental protocol, circadian rhythms will be assessed in two ways; 1) Actigraphy and 2) Clock gene expression in buccal cell swabs. Acticals will be worn throughout to gather sleep variables (timing, duration, quality). Clock gene expression (CLOCK, BMAL1, PER2) will be measured in swabs taken from the cheek at 6 hour intervals (00:00, 06:00, 12:00, 18:00) to assess the effects of sleep deprivation on the molecular circadian rhythm. Cheek swabs will be immediately placed in RNA stabilization buffer until isolation. Swabs taken at 00:00 will be performed with minimal exposure to light to avoid disruption of sleep. These methods have been used previously to assess normal and disrupted sleep.

Interventions

BEHAVIORALSleep Restriction

Participants will be allowed \ 4 hour sleep opportunity during the restricted night of sleep prior to reporting to lab for a simulated firefighting session.

BEHAVIORALNormal Sleep

Participants will be allowed \ 8 hour sleep opportunity the night of sleep prior to reporting to lab for a simulated firefighting session.

Sponsors

University of Nevada, Las Vegas
CollaboratorOTHER
University of Montana
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

Randomized cross-over design

Eligibility

Sex/Gender
MALE
Age
18 Years to 44 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy * Male * 18 - 44 years of age

Exclusion criteria

* Preexisting cardiometabolic and/or pulmonary diseases * Preexisting sleep disorder * Smoking (current or within last year)

Design outcomes

Primary

MeasureTime frameDescription
Blood Inflammationsamples collected at baseline, immediately post exposureIL-6 will be measured in the plasma

Secondary

MeasureTime frameDescription
Exhaled Breath Condensate Pentraxin-3samples collected at baseline, immediately post exposurePentraxin-3 will be measured in EBC of participants at baseline (PRE) and after exercise (POST) on two trial days. One trial day will be after a normal night of sleep (Normal Sleep) and the other trial will be after sleep restriction to 4 hours (Restricted Sleep). The value is determined through ELISA method, represented in ng/mL, where higher levels indicate worse response.

Countries

United States

Participant flow

Participants by arm

ArmCount
Normal Sleep (With 250 ug/m^3 PM2.5) Then Restricted Sleep (With 250 ug/m^3 PM2.5)
Participants will complete two sessions in the lab. During their first session, they will have a normal sleep opportunity the night prior to reporting to the lab for the simulated firefighting session (250 ug/m\^3 PM2.5 with moderate intensity exercise). Normal Sleep: Participants will be allowed \ 8 hour sleep opportunity the night of sleep prior to reporting to lab for a simulated firefighting session. During their second session, participants will have a restricted sleep opportunity (\ 4 hours) the night prior to reporting to the lab for the simulated firefighting session (250 ug/m\^3 PM2.5 with moderate intensity exercise). Sleep Restriction: Participants will be allowed \ 4 hour sleep opportunity during the restricted night of sleep prior to reporting to lab for a simulated firefighting session.
5
Restricted Sleep (With 250 ug/m^3 PM2.5) Then Normal Sleep (With 250 ug/m^3 PM2.5)
Participants will complete two sessions in the lab. During their first session, participants will have a restricted sleep opportunity (\ 4 hours) the night prior to reporting to the lab for the simulated firefighting session (250 ug/m\^3 PM2.5 with moderate intensity exercise). Sleep Restriction: Participants will be allowed \ 4 hour sleep opportunity during the restricted night of sleep prior to reporting to lab for a simulated firefighting session. During their second session, participants will have a normal sleep opportunity the night prior to reporting to the lab for the simulated firefighting session (250 ug/m\^3 PM2.5 with moderate intensity exercise). Normal Sleep: Participants will be allowed \ 8 hour sleep opportunity the night of sleep prior to reporting to lab for a simulated firefighting session.
5
Total10

Baseline characteristics

CharacteristicNormal Sleep (With 250 ug/m^3 PM2.5) Then Restricted Sleep (With 250 ug/m^3 PM2.5)Restricted Sleep (With 250 ug/m^3 PM2.5) Then Normal Sleep (With 250 ug/m^3 PM2.5)Total
Age, Continuous23.8 years
STANDARD_DEVIATION 3.56
25.0 years
STANDARD_DEVIATION 5
24.4 years
STANDARD_DEVIATION 4.1
Blood IL-60.69 pg/mL
STANDARD_DEVIATION 0.31
0.80 pg/mL
STANDARD_DEVIATION 0.79
0.75 pg/mL
STANDARD_DEVIATION 0.59
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
5 Participants5 Participants10 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
5 Participants5 Participants10 Participants
Region of Enrollment
United States
5 participants5 participants10 participants
Sex: Female, Male
Female
0 Participants0 Participants0 Participants
Sex: Female, Male
Male
5 Participants5 Participants10 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 100 / 10
other
Total, other adverse events
0 / 100 / 10
serious
Total, serious adverse events
0 / 100 / 10

Outcome results

Primary

Blood Inflammation

IL-6 will be measured in the plasma

Time frame: samples collected at baseline, immediately post exposure

Population: Blood plasma was used to measure IL-6 using a commercially available ELISA.

ArmMeasureGroupValue (MEAN)Dispersion
Normal Sleep (With 250 ug/m^3 PM2.5)Blood InflammationBaseline0.69 pg/mLStandard Error 0.1
Normal Sleep (With 250 ug/m^3 PM2.5)Blood InflammationPOST2.33 pg/mLStandard Error 0.33
Restricted Sleep (With 250 ug/m^3 PM2.5)Blood InflammationBaseline0.79 pg/mLStandard Error 0.25
Restricted Sleep (With 250 ug/m^3 PM2.5)Blood InflammationPOST1.63 pg/mLStandard Error 0.25
p-value: <0.05ANOVA
Secondary

Exhaled Breath Condensate Pentraxin-3

Pentraxin-3 will be measured in EBC of participants at baseline (PRE) and after exercise (POST) on two trial days. One trial day will be after a normal night of sleep (Normal Sleep) and the other trial will be after sleep restriction to 4 hours (Restricted Sleep). The value is determined through ELISA method, represented in ng/mL, where higher levels indicate worse response.

Time frame: samples collected at baseline, immediately post exposure

ArmMeasureGroupValue (MEAN)Dispersion
Normal Sleep (With 250 ug/m^3 PM2.5)Exhaled Breath Condensate Pentraxin-3PRE0.97 ng/mLStandard Deviation 0.04
Normal Sleep (With 250 ug/m^3 PM2.5)Exhaled Breath Condensate Pentraxin-3POST0.96 ng/mLStandard Deviation 0.02
Restricted Sleep (With 250 ug/m^3 PM2.5)Exhaled Breath Condensate Pentraxin-3POST0.96 ng/mLStandard Deviation 0.03
Restricted Sleep (With 250 ug/m^3 PM2.5)Exhaled Breath Condensate Pentraxin-3PRE0.95 ng/mLStandard Deviation 0.02
p-value: >0.05ANOVA

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026